Xenon Pharmaceuticals Inc.
For the period ended Jun 30, 2025. Filed Aug 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 11, 2025
XENE$40.45+3.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(Expressed in thousands of U.S. dollars except share amounts)
| June 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $135,381 | $142,712 |
| Marketable securities (note 5) | 352,164 | 484,193 |
| Other receivables | 1,097 | 1,469 |
| Prepaid expenses and other current assets | 11,610 | 6,890 |
| Total current assets | 500,252 | 635,264 |
| Marketable securities, long-term (note 5) | 137,297 | 127,496 |
| Operating lease right-of-use asset, net (note 6) | 7,290 | 7,939 |
| Property, plant and equipment, net | 9,205 | 10,278 |
| Deferred tax assets | 11,049 | 9,666 |
| Prepaid expenses, long-term | 9,188 | 7,496 |
| Total assets | $674,281 | $798,139 |
| Liabilities and shareholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities (note 7) | $31,588 | $34,221 |
| Operating lease liability (note 6) | 1,459 | 1,369 |
| Total current liabilities | 33,047 | 35,590 |
| Operating lease liability, long-term (note 6) | 7,256 | 7,646 |
| Total liabilities | 40,303 | 43,236 |
| Shareholders’ equity: | ||
| Common shares, without par value; unlimited shares authorized; issued and outstanding: 76,939,811 (December 31, 2024 - 76,416,086) (note 8) | 1,469,196 | 1,456,836 |
| Additional paid-in capital | 213,892 | 199,149 |
| Accumulated deficit | (1,049,223) | (899,470) |
| Accumulated other comprehensive income (loss) | 113 | (1,612) |
| Total shareholders’ equity | 633,978 | 754,903 |
| Total liabilities and shareholders’ equity | $674,281 | $798,139 |
| Commitments and contingencies (note 11) | ||
-3-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.